Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Paul Franks

Paul Franks

Principal investigator

Paul Franks

Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program

Author

  • Tibor V. Varga
  • Alexandra H. Winters
  • Kathleen A. Jablonski
  • Edward S. Horton
  • Prajakta Khare-Ranade
  • William C. Knowler
  • Santica M. Marcovina
  • Frida Renström
  • Karol E. Watson
  • Ronald Goldberg
  • José C. Florez
  • Toni I. Pollin
  • Paul W. Franks

Summary, in English

Background-We assessed whether 234 established dyslipidemia-associated loci modify the effects of metformin treatment and lifestyle intervention (versus placebo control) on lipid and lipid subfraction levels in the Diabetes Prevention Program randomized controlled trial. Methods and Results-We tested gene treatment interactions in relation to baseline-adjusted follow-up blood lipid concentrations (high-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol, and triglycerides) and lipoprotein subfraction particle concentrations and size in 2993 participants with pre-diabetes. Of the previously reported single-nucleotide polymorphism associations, 32.5% replicated at P<0.05 with baseline lipid traits. Trait-specific genetic risk scores were robustly associated (3×10-4>P>1.1×10-16) with their respective baseline traits for all but 2 traits. Lifestyle modified the effect of the genetic risk score for large HDL particle numbers, such that each risk allele of the genetic risk scores was associated with lower concentrations of large HDL particles at follow-up in the lifestyle arm (β=-0.11 μmol/L per genetic risk scores risk allele; 95% confidence interval,-0.188 to-0.033; P=5×10-3; Pinteraction=1×10-3 for lifestyle versus placebo), but not in the metformin or placebo arms (P>0.05). In the lifestyle arm, participants with high genetic risk had more favorable or similar trait levels at 1-year compared with participants at lower genetic risk at baseline for 17 of the 20 traits. Conclusions-Improvements in large HDL particle concentrations conferred by lifestyle may be diminished by genetic factors. Lifestyle intervention, however, was successful in offsetting unfavorable genetic loading for most lipid traits. Clinical Trial Registration-URL: https://www.clinicaltrials.gov. Unique Identifier: NCT00004992.

Department/s

  • Genetic and Molecular Epidemiology
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2016-12-01

Language

English

Pages

495-503

Publication/Series

Circulation: Cardiovascular Genetics

Volume

9

Issue

6

Document type

Journal article

Publisher

American Heart Association

Topic

  • Endocrinology and Diabetes
  • Cardiac and Cardiovascular Systems

Keywords

  • clinical trial
  • genetics
  • lifestyle
  • lipids
  • lipoproteins
  • molecular epidemiology
  • polymorphism, genetic

Status

Published

Research group

  • Genetic and Molecular Epidemiology

ISBN/ISSN/Other

  • ISSN: 1942-325X